<--- Back to Details
First PageDocument Content
Health / Cancer / Chemistry / National Institutes of Health / Medivation / Enzalutamide / Medical research / Astellas Pharma / Prostate cancer / Pharmaceutical industry / Food and Drug Administration / BayhDole Act
Date: 2016-04-28 17:01:28
Health
Cancer
Chemistry
National Institutes of Health
Medivation
Enzalutamide
Medical research
Astellas Pharma
Prostate cancer
Pharmaceutical industry
Food and Drug Administration
BayhDole Act

Add to Reading List

Source URL: keionline.org

Download Document from Source Website

File Size: 260,50 KB

Share Document on Facebook

Similar Documents

Uncertainty evaluation of image-based tumour control probability models in radiotherapy of prostate cancer using a visual analytic tool

DocID: 1vnrm - View Document

Abstract # 3991 Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond CellCentric

DocID: 1vi4a - View Document

Spring 2014 Issue YES TO LIFE YOUR OPTIONS FOR CANCER Dear Friends and Supporters, In the last Newsletter, we told you about our autumn London Seminar on prostate cancer, the first of our

DocID: 1v4PI - View Document

CANINE BLADDER CANCER by Deborah W. Knapp, DVM, Dipl. ACVIM Cancer of the urinary tract in dogs can affect the kidneys, ureters, urinary bladder, prostate, or urethra (see Figure 1). Within the urinary

DocID: 1uUAX - View Document

EDITORIAL Prostate cancer and selective serotonin reuptake inhibitors Alka Aggarwal Aggarwal A. Prostate cancer and selective serotonin reuptake inhibitors.Ann Histol Surg Pathol. 2017;1(1)5.

DocID: 1uKru - View Document